Under construction – not a live service
Sign in
Taking people in DenmarkPhase 2

Testing glimepiride dose increases in HNF1A and HNF4A diabetes

Tests higher glimepiride doses in adults with HNF1A or HNF4A MODY diabetes.

Key facts

Who runs it
Steno Diabetes Center Copenhagen
Where
Aarhus N and Herlev, DenmarkSee the 2 sites
Registry title
Up-titration of sulfonylurea (SU) in individuals with HNF1A- and HNF4A-MODY – A Steno MODERN-MODY project (MM-SUUP)
Status
Recruiting
Phase
Phase 2
People taking part
30 people, planned
Started
14 Apr 2026
Expected to end
1 Dec 2027
Type of study
Interventional
Record updated
4 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with diabetes caused by a proven HNF1A or HNF4A gene change (MODY), to test higher doses of glimepiride.

Age
18 years or older
Sex
Women and men can join.
Disease stage
Diabetes with HbA1c of 48 mmol/mol (6.5%) or higher, and/or current insulin treatment.
Earlier treatment
Cannot have taken a sulfonylurea (SU) or glinide drug in the last 30 days.
Biomarker or test result
A heterozygous mutation (pathogenic or likely pathogenic by ACMG criteria) in the HNF1A gene or the HNF4A gene.

Main reasons for not taking part

  • Breastfeeding, pregnancy, or not using adequate contraception when able to have children
  • Kidney disease (eGFR below 30 ml/min/1.73 m2 and/or severely raised albumin in the urine)
  • End-stage liver disease
  • Cannot use the continuous glucose monitoring (CGM) device, for example due to skin reactions
  • Known allergy to glimepiride or other sulphonamides

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • HbA1c ≥48 mmol/mol and/or current insulin treatment
  • Age ≥18 years
  • Diabetes caused by a heterozygous mutation (pathogenic or likely pathogenic according to ACMG criteria) in the HNF1A-gene or HNF4A-gene
  • Informed consent

Who cannot take part

  • Treatment with SU or glinides within the last 30 days
  • End-stage liver disease
  • Known allergic reaction to study drug (glimepiride or other sulphonamides)
  • Nephropathy (eGFR <30 ml/min/1.73 m2 and/or persistent severely increased albuminuria (urine-albumin-creatinine ratio >300 mg/g))
  • Breastfeeding, pregnancy or inadequate contraceptive methods in women with childbearing potential
  • Contraindications for use of specific CGM device (e.g. non-manageable skin reactions, use of substances interfering with measurements etc.)

Where in Denmark

  • Aarhus University HospitalAarhus N, DenmarkTaking people
  • Steno Diabetes Center CopenhagenHerlev, DenmarkTaking people

About the trial

What the trial wants to find out

We aim to systematically assess the effects of up-titration of glimepiride on continuous glucose monitoring (CGM) metrics in individuals diagnosed with HNF1A- or HNF4A-MODY including those who have previously been treated as individuals with T1D or T2D.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Up-titration of sulfonylurea (SU) in individuals with HNF1A- and HNF4A-MODY – A Steno MODERN-MODY project (MM-SUUP)
Plain-language title
Testing glimepiride dose increases in HNF1A and HNF4A diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
4 March 2026